Instil Bio — Third Quarter 2026 Earnings Summary
Financial Performance:
- Net loss for the three months ended September 30, 2026, was $4.2 million ($0.62 per share), compared to $13.6 million ($2.01 per share) in the same period in 2025.
- Net loss for the nine months ended September 30, 2026, was $13.0 million ($1.92 per share), compared to $63.5 million ($9.58 per share) in the same period in 2025.
- Non-GAAP net loss for the three months ended September 30, 2026, was $3.3 million ($0.48 per share), compared to $11.8 million ($1.75 per share) in 2025.
- Non-GAAP net loss for the nine months ended September 30, 2026, was $8.9 million ($1.32 per share), compared to $39.8 million ($6.00 per share) in 2025.
- Research and development expenses were $0.2 million for the three months ended September 30, 2026, compared to $9.1 million in 2025; $1.2 million for the nine months ended September 30, 2026, compared to $21.2 million in 2025.
- General and administrative expenses were $5.8 million for the three months ended September 30, 2026, compared to $6.3 million in 2025; $17.5 million for the nine months ended September 30, 2026, compared to $22.7 million in 2025.
- Restructuring and impairment charges, net, included a reversal of $0.1 million for the three months ended September 30, 2026, compared to nil in 2025; and a charge of $1.1 million for the nine months ended September 30, 2026, compared to $16.6 million in 2025.
- In-process research and development expenses were nil for both the three and nine months ended September 30, 2026, compared to nil and $10.0 million, respectively, in 2025.
- Cash, cash equivalents, restricted cash, marketable securities, and long-term investments totaled $67.1 million as of September 30, 2026, down from $76.3 million as of December 31, 2025.
- Total assets were $195.6 million as of September 30, 2026, compared to $204.5 million as of December 31, 2025.
- Total stockholders' equity was $102.6 million as of September 30, 2026, compared to $112.7 million as of December 31, 2025.
- Interest income was $0.6 million for the three months ended September 30, 2026, compared to $0.9 million in 2025; $1.9 million for the nine months ended September 30, 2026, compared to $3.1 million in 2025.
- Other rental income was $2.7 million for the three months ended September 30, 2026, compared to $2.7 million in 2025; $8.1 million for the nine months ended September 30, 2026, compared to $8.1 million in 2025.
- A gain on contract termination of $1.6 million was recorded for the nine months ended September 30, 2026, with no comparable amount in 2025.
Guidance and Future Outlook:
- Instil expects its cash position of $67.1 million as of September 30, 2026, will fund its current operating plan through 2027.
- The company intends to establish a portfolio of asset-focused development subsidiaries by internally developing or in-licensing programs.
Business Segments and Product Lines:
- The company operates under an asset-focused development model, aiming to build a diversified portfolio of development candidates.
- No specific product line performance metrics or new product launch details were provided in the release.
Market and Competitive Landscape:
- No specific market share, competitive landscape, or market trend data was provided in the release.
Risks and Challenges:
- Risks include the sufficiency of cash resources, pursuing potential transactions to acquire companies or in-license product candidates, and macroeconomic factors such as interest rates and inflation.
- The company identified errors in previously issued financial statements regarding property taxes on its Tarzana, California facility and the presentation of tenant reimbursements, though these were not material to any previously issued financial statements.
Management Commentary and Tone:
- Management highlighted the company's strategy to combine focused teams with strategic support to develop novel therapies for unmet medical needs.
- The release notes that the 2025 amounts presented in the financial data have been corrected for the identified errors.
Other Key Points:
- The press release includes a correction of prior-period information in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and the 2025 amounts in this release are presented as corrected.
- Non-GAAP financial measures exclude non-cash stock-based compensation expense and restructuring and impairment charges, net.
- The company is building a portfolio of asset-focused subsidiaries to develop novel therapies.
- Company
- INSTIL BIO INC
- Sector
- Healthcare
- Industry
- Biotechnology